Victory Capital Management Inc. purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 19,152 shares of the company’s stock, valued at approximately $676,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Concurrent Investment Advisors LLC acquired a new position in Dyne Therapeutics during the 1st quarter worth about $573,000. Sei Investments Co. acquired a new position in shares of Dyne Therapeutics in the first quarter worth approximately $693,000. Rafferty Asset Management LLC boosted its holdings in Dyne Therapeutics by 17.7% in the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after acquiring an additional 24,632 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Dyne Therapeutics during the 1st quarter valued at approximately $810,000. Finally, Commodore Capital LP bought a new position in Dyne Therapeutics during the 4th quarter worth approximately $11,970,000. 96.68% of the stock is currently owned by institutional investors.
Insider Transactions at Dyne Therapeutics
In related news, insider Oxana Beskrovnaya sold 2,339 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the transaction, the insider now owns 140,375 shares of the company’s stock, valued at $4,849,956.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,339 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $80,812.45. Following the completion of the sale, the insider now directly owns 140,375 shares of the company’s stock, valued at approximately $4,849,956.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the transaction, the chief operating officer now directly owns 148,792 shares in the company, valued at approximately $5,256,821.36. The disclosure for this sale can be found here. Insiders sold a total of 22,868 shares of company stock valued at $796,760 over the last three months. Corporate insiders own 20.77% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on Dyne Therapeutics
Dyne Therapeutics Stock Performance
Shares of Dyne Therapeutics stock opened at $36.59 on Friday. The stock has a market capitalization of $3.20 billion, a PE ratio of -9.22 and a beta of 1.07. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $47.45. The stock has a 50 day moving average price of $41.07 and a two-hundred day moving average price of $33.61.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. Research analysts forecast that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.
Dyne Therapeutics Profile
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
See Also
- Five stocks we like better than Dyne Therapeutics
- Why Are Stock Sectors Important to Successful Investing?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- MarketBeat Week in Review – 9/16 – 9/20
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report).
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.